F 16915 |
| Catalog No.GC34039 |
Le F 16915, un dérivé de l'acide docosahexaénoÏque, est un puissant promédicament du DHA.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 92510-91-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation.
F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation. Time-dependent changes in blood concentrations of total docosahexaenoic acid (DHA) and nicotinyl alcohol are followed after a single oral administration of F 16915 (300 mg/kg) to male rats. Treatment with F 16915 has no significant effect on body weight: 27.7±2.9 kg and 28.1±1.0 kg before surgery versus 29.2±3.4 kg and 28.8±1.7 kg after in the 1 and 5 g/day groups, respectively. F 16915 administered at 5 g/day for 4 weeks significantly reduces the mean duration of Atrial fibrillation (AF) induced by burst pacing but has no significant effect at 1 g/day. The duration of AF is significantly reduced from 989±111 s in the placebo group to 79±59 s in the presence of F 16915 at 5 g/day. Treatment of 2 months with 100 mg/kg F 16915 also significantly reduces the infarct size[1].
[1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *